Printer Friendly

MEDTRONIC REPORTS REGULATORY ACTION ON TACHYARRHTHMIA DEVICE

 MEDTRONIC REPORTS REGULATORY ACTION ON TACHYARRHTHMIA DEVICE
 MINNEAPOLIS, Sept. 16 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT) said today that it had received an "approvable" letter from the U.S. Food and Drug
Administration (FDA) for the PCD(TM) device with epicardial leads. This is the last step in the regulatory process before final FDA clearance for marketing in the United States.
 Company officials stressed that timing of final FDA clearance is difficult to predict.
 The PCD, an implantable system designed to deliver tiered therapy for hearts that beat abnormally fast, has been marketed in Europe since March of 1991. It also has been cleared by regulatory authorities in Canada.
 Medtronic, Inc., headquartered in Minneapolis, is a leading developer and manufacturer of biomedical devices for improving cardiovascular and neurological health.
 -0- 9/16/92
 /CONTACT: Dale Beumer, investor relations, 612-574-3038, or Dick Reid, public relations, 612-574-3052, both of Medtronic/
 (MDT) CO: Medtronic, Inc. ST: Minnesota IN: MTC SU:


AL -- MN005 -- 0145 09/16/92 12:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1992
Words:165
Previous Article:GERIATRIC & MEDICAL CENTERS REPORTS FOURTH QUARTER FISCAL YEAR ENDED 1992 RESULTS
Next Article:1992 ANNUAL MEETING ADDRESSES BLUE CROSS AND BLUE SHIELD OF FLORIDA'S FINANCIAL STRENGTH
Topics:


Related Articles
PANEL CONSIDERATION DOUBTFUL FOR MEDTRONIC PCD DEVICE AT NOVEMBER MEETING
MEDTRONIC NAMES PETER A. CHEVALIER VICE PRESIDENT, REGULATORY AFFAIRS
MEDTRONIC NAMES CHEVALIER AND HALVERSON TO CORPORATE QUALITY, REGULATORY POSITIONS
FORMER EMPI, MEDTRONIC REGULATORY PERSON JOINS ANGEION AS VICE PRESIDENT, REGULATORY AND CLINICAL AFFAIRS
MEDTRONIC ANNOUNCES THREE MILESTONES IN DEVELOPMENT OF NEW TACHYARRHYTHMIA DEVICES
MEDTRONIC DISAPPOINTED BY HIGH COURT DECISION; EXPECTS NO SIGNIFICANT FINANCIAL IMPACT
Medtronic Reports First-Quarter Earnings Per Share of $0.32, Consistent With Earlier Announcement
Medtronic Expects Major Expansion In Cardiac Rhythm Management Sales Organization
Medtronic and Arterial Vascular Engineering (AVE) Note End of Regulatory Waiting Period.
Medtronic receives FDA approval smaller implantable pump for chronic pain, severe spasticity.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters